Oral mucositis. Oral mucositis (ulcerative) due to antineoplastic therapy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged 6 to 18 years diagnosed with various cancers and hospitalized at Amir Hospital,Had Grade 2 or higher mucositis in previous chemotherapy that Fully recovered before the start of the study Maintain oral hygiene
Exclusion criteria
Exclusion criteria: Allergy to any components of the drugs Systemic liver and kidney disease and diabetes involvement of mucosa and skin by another disease, or viral and fungal oral infection Failure to complete the consent form Grade 4 mucositis autoimmune or rheumatologic diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in the incidence and severity of oral mucositis. Timepoint: Evaluation of mucositis at the beginning of the study before the start of the study and on days 5, 10, and 14. Method of measurement: All patients initially complete the WHO-validated oral mucositis questionnaire, and their scores are recorded. Only patients with a score of zero are enrolled in the study. Patients are regularly evaluated by a specialist assessor, and the CHIMES questionnaire (Chemotherapy-Induced Mucositis Evaluation Scale) is also completed to monitor disease-related complications. | — |
Secondary
| Measure | Time frame |
|---|---|
| Acceptance of patients in terms of taste and appearance characteristics of the muco-adherent mouthwash / Reduction in the duration of oral mucositis / improvment in patients quality of life. Timepoint: Evaluation of mucositis at the beginning of the study before the start of the study and on days 5, 10, and 14. Method of measurement: All patients initially complete the WHO-validated oral mucositis questionnaire, and their scores are recorded. Only patients with a score of zero are enrolled in the study. Patients are regularly evaluated by a specialist assessor, and the CHIMES questionnaire (Chemotherapy-Induced Mucositis Evaluation Scale) is also completed to monitor disease-related complications. | — |
Countries
Iran (Islamic Republic of)
Contacts
Shiraz University of Medical Sciences